Free Biopharma Daily Stock Updates - 03/23/21

$XBI $138.54 -6%

Want to access our searchable database of over 900 catalyst events and more? Try BiopharmIQ for 30 days free, no credit card required. Check it out here!

Covid Updates

$OMER -1% Dosing of patients with narsoplimab for covid-19 started earlier this month. source


$AZN -3% Update on validating covid-19 data announced yesterday. source


Pipeline Updates

$ORMP +5% Initiates ph 3 oral insulin study under FDA approved protocol. source


$PGEN -6% Fist patient dosed for PRGN-2012 in recurrent respiratory papillomatosis (RRP). source


$LCTX -1% Interim results from ongoing ph 1/2a study of OpRegen. source


$AKRO -4% First patient randomized for dosing in ph 2b study of efruxifermin in NASH. source


$VTVT 6% Patent 10,952,993 issued for TTP399. source


$ASND -4% Data from 6-mo open-label ph 2 study of TransCon. source


$FREQ -78% Topline data from ph 2a study for FX-322. source


$IDYA -2% Dose expansion in ph 1/2 study of IDE196 and binimetinib. source


Financial Updates

$PRTA -12% Public offering. source


$XOMA -4% purchased future milestones and royalties associated with licenses for DAY101 and vosaroxin. source

0 comments

*Disclaimer: Information provided on bpiq.com and in any of our reports, products and services are for information only and are not investment advice. Please consult with an investment adviser and do your own diligence before making any investment decisions or taking any action.  By accessing this site, you agree to our Terms of Use and Privacy Policy that can be accessed here. Big Movers™ is a trademark of Amp Biotech Research, LLC

©2021 by Biopharm IQ. Website by Awaken Studio.

SITE